InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,732.93
(
0.25%
)
US TECH 100
19,338.80
(
-0.39%
)
Dow Jones
42,208.22
(
0.20%
)
Brent Oil
74.64
(
0.10%
)
Bitcoin
63,822.27
(
-0.69%
)
Post# of 7747
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

zino

Send PM Follow Ignore
Followers 339
Posts 19337
Boards Moderated 0
Alias Born 08/25/2007

zino

Re: None

Wednesday, 06/21/2017 1:54:24 PM

Wednesday, June 21, 2017 1:54:24 PM

Post# of 7747
Massive Drug Trial Results Wow !!!!
Median progression-free survival of 5.32 months compared to 2.96 months for investigator's choice therapy

Statistically significant difference (p=0.007) with a 38% reduction in the risk of tumor progression (hazard ratio = 0.62).

Safety front, aldoxorubicin caused no clinically significant cardiac, renal or hepatic toxicities

DONT LISTEN TO ME IM CANADIANNNNNNNN

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up